|
End-of-day quote
Mexican S.E.
2026-09-25
|
5-day change | 1st Jan Change | ||
| 2,572.00 MXN | +5.24% |
|
+5.24% | +2.88% |
| 08:27am | Novartis AG : Receives a Sell rating from Goldman Sachs | ZD |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | ||
| 1,328.83 | +14.84% | 29 | ||||||
| 279.27 | +5.49% | 22 | ||||||
| 278.86 | +6.6% | 28 | ||||||
| 155.76 | +7.19% | 25 | ||||||
| 375.34 | +7.52% | 19 | ||||||
| 152.29 | +5.92% | 22 | ||||||
| 210.66 | +29.21% | 23 | ||||||
| 390.94 | -7.25% | 29 | ||||||
| 158.65 | +6.44% | 26 | ||||||
| 307.56 | +21.47% | 23 | ||||||
| 28.88 | +1.24% | 26 | ||||||
| 571.39 | +9.29% | 28 | ||||||
| 66.71 | +6.9% | 24 | ||||||
| 979.36 | +14.7% | 14 | ||||||
| 21.75 | +18.71% | 21 | ||||||
| 94.06 | +29.49% | 24 | ||||||
| 120.67 | -37.34% | 18 | ||||||
| 850.88 | +12.21% | 26 | ||||||
| 154.21 | +11.67% | 14 | ||||||
| Average | 343.48 | +8.65% | 23 | ||||||
| Weighted average by Cap. | 493.89 | +9.55% | 25 |
- Stock Market
- Stocks
- NOVN Stock
- NVS N Stock
- Sector Novartis AG
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
